| Metric | Value | Detail |
|---|---|---|
| Revenue | $36.4B | +8.4% YoY |
| Net income | $4.8B | 13.3% margin |
| Gross margin | n/a | Gross profit / revenue |
| Operating margin | 17.8% | Operating income / revenue |
| Return on equity | 10% | Net income / equity |
| Return on assets | 5% | Net income / assets |
| Revenue growth (YoY) | +8.4% | FY2025 to FY2026 |
| Revenue 3-yr CAGR | +5.2% | Compound annual |
| Diluted EPS | $3.75 | FY2026 |
| Debt-to-equity | n/a | Long-term debt / equity |
| Current ratio | 2.13 | Current assets / liabilities |
| Cash & equivalents | $1.9B | Balance sheet |
| Total assets | $93.0B | FY2026 year-end |
| Shareholders’ equity | $50.1B | FY2026 year-end |
| Share price | $83.87 | Delayed · 2026-07-10 |
| Market cap | $107.4B | Price × shares outstanding |
| P/E ratio | 22.2 | Market cap / net income |
| P/S ratio | 3.0 | Market cap / revenue |
| Dividend yield | 3.39% | Dividend / price |
Stock fundamentals · FY2026 · SEC 10-K data
Medtronic plc (MDT) stock fundamentals
Medtronic plc (MDT) reported $36.4B in revenue and $4.8B in net income in fiscal 2026, a 13.3% net margin, per its latest SEC 10-K filing. It carries a market capitalization of about $107.4B at a delayed share price. It scores 50/100 on WealthyBud's Investor Score, ranking #47 of 100 covered companies. Score is research, not investment advice.
Revenue (FY2026)
$36.4B
▲ +8.4% YoY
Net income
$4.8B
13.3% net margin
Market cap
$107.4B
Price $83.87 · delayed
P/E ratio
22.2
Price / earnings
Return on equity
10%
Net income / equity
Investor Score
50/100
#47 of 100 covered
Medtronic plc fundamentals at a glance
The table summarizes Medtronic plc's key financial figures for fiscal 2026 — revenue, profitability, returns, growth and balance-sheet strength — each taken from the company's SEC 10-K filing.
How profitable is Medtronic plc?
Medtronic plc runs a 13.3% net margin and n/a gross margin in fiscal 2026, turning $36.4B of revenue into $4.8B of profit. Return on equity is 10% and return on assets 5%.
Is Medtronic plc growing?
Medtronic plc's revenue changed +8.4% in fiscal 2026 and compounded at +5.2% a year over three years, reaching $36.4B. Diluted earnings per share were $3.75 for the year.
| Fiscal year | Revenue | Growth |
|---|---|---|
| 2022 | $31.7B | n/a |
| 2023 | $31.2B | -1.4% |
| 2024 | $32.4B | +3.6% |
| 2025 | $33.5B | +3.6% |
| 2026 | $36.4B | +8.4% |
How is Medtronic plc valued?
Medtronic plc carries a market capitalization of $107.4B at a delayed share price of $83.87, trading at a 22.2 price-to-earnings ratio and 3.0 price-to-sales with a 3.39% dividend yield. Its Value subscore is 73/100 across the covered universe.
How financially healthy is Medtronic plc?
Medtronic plc ended fiscal 2026 with $1.9B in cash, a debt-to-equity ratio of n/a and a current ratio of 2.13. Lower leverage and a current ratio above 1.0 signal a stronger balance sheet.
What is Medtronic plc's Investor Score?
Medtronic plc scores 50/100 on WealthyBud's Investor Score, #47 of 100 covered companies as of 2026-07-10. The score blends growth, profitability, returns on capital, balance-sheet strength and value into one percentile. It is a research opinion, not investment advice.
Investor Score
50/100
#47 of 100 covered companies
Subscores are percentile ranks (0–100) across the 100 covered companies, computed from the SEC fundamentals and delayed market price cited on this page. Data-derived opinion, not investment advice.
Medtronic plc (MDT) stock FAQ
How much revenue does Medtronic plc make?
Medtronic plc (MDT) reported $36.4B in revenue in fiscal 2026, +8.4% versus the prior year, according to its SEC 10-K filing. Over the past three years its revenue has compounded at +5.2% a year.
Is Medtronic plc profitable?
Yes. Medtronic plc earned $4.8B in net income in fiscal 2026, a 13.3% net margin. Its return on equity was 10% and return on assets 5%, based on figures from its latest 10-K.
How fast is Medtronic plc growing?
Medtronic plc's revenue changed +8.4% year over year in fiscal 2026 and compounded at +5.2% annually over three years. Growth is one of four inputs to its WealthyBud Investor Score, scored 52/100 versus the covered universe.
What is Medtronic plc's market cap and P/E ratio?
Medtronic plc has a market capitalization of $107.4B at a delayed share price of $83.87, trading at a price-to-earnings ratio of 22.2 and price-to-sales of 3.0. Its dividend yield is 3.39%. Prices are delayed and illustrative.
What is Medtronic plc's WealthyBud Investor Score?
Medtronic plc scores 50/100, ranking #47 of 100 covered companies as of 2026-07-10. The score is a percentile blend of growth (52), profitability (38), returns on capital (21), balance-sheet strength (82) and value (73). It is a research opinion, not investment advice.
Where does this Medtronic plc financial data come from?
Fundamentals come from Medtronic plc's annual report (Form 10-K) filed with the SEC, via the public-domain EDGAR database. The share price used for market cap, P/E and yield is a delayed end-of-day quote, shown as illustrative; a production site would use a licensed real-time market-data feed.
Fundamentals are drawn from Medtronic plc’s FY2026 Form 10-K filed with the
SEC (EDGAR, public domain), retrieved 2026-07-10. Share price is a delayed end-of-day quote; market cap, P/E, P/S
and dividend yield are illustrative and not real-time. The Investor Score is a data-derived research opinion.
Not investment advice.